Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma
2011-01-01 Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J
Estratto della tesi di dottorato: “Il principio del vivente nelle anonime Questiones super librum de anima (ms. Siena, Bibl. Com. degli Intronati L.III.21, ff. 136ra-174ra”,
2005-01-01 Bernardini, Paola
Guest Editorial “Secure lightweight crypto-hardware”
2017-01-01 Acosta, A.; Addabbo, T.
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy
2019-01-01 Bargagli, E; Bergantini, L; Cameli, P; D'Alessandro, M; Bini, L; Rottoli, P; Landi, C
Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European expanded access programme (EAP)
2012-01-01 Maio, M; Chiarion Sileni, V; Pilla, L; Nicoletti, Svl; Di Guardo, L; Queirolo, P; De Galitiis, F; Mandala, M; Guida, M; Ascierto, Pa
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases
2012-01-01 Maio, M; Testori, A; Ascierto, Pa; Ridolfi, R; Santinami, M; Pilla, L; Queirolo, P; Grosso, M; Simeone, E; Vittoria, S; Nicoletti, L; Rivoltini, L; Ferrucci, Pf; Parmiani, G; DI GIACOMO, ANNA MARIA
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma
2012-01-01 Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)
2011-01-01 Johnston, K; Levy, Ar; Lorigan, P; Maio, M; Lebbé, C; Middleton, M; Testori, A; Bédane, C; Konto, C; Dueymes, A; van Baardewijk, M
Morphological and functional characterization of IL12 Receptor beta2 chain on intestinal epithelial cells: implications for local and systemic immunoregulation
2018-01-01 Nicoletti, C.; Regoli, M.; Pacini, A.; Branca, J. J. V.; Man, A. L.; Morucii, G.; Narbad, A.; Gulisano, M.; Bertelli, E.
Guidelines Versus Measurements in Real Setting: Modelling Microbial Airborne Contamination and Air Flow in Operating Theaters
2018-01-01 Vonci, Niccolò; Spataro, Giuseppe; De Marco, Maria Francesca; Nante, Nicola; Cevenini, Gabriele; Messina, Gabriele
Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma
2013-01-01 Maio, M; Bondarenko, I; Robert, C; Thomas, L; Garbe, C; Testori, A; Lu, H; Chin, K; Wolchok, J
Five-year survival rates for patients (pts) with metastatic melanoma (mm) treated with ipilimumab (ipi) in phase II trials
2012-01-01 Lebbe, C; Weber, Js; Maio, M; Neyns, B; Harmankaya, K; Chin, K; Mcdowell, Do; Cykowski, L; Mchenry, Mb; Wolchok, Jd
Expression of p34(cdc2) and cyclin B-1 in Hodgkin's disease and anaplastic large cell lymphomas
1997-01-01 Leoncini, L.; Megha, T.; Lazzi, S.; Bellan, C.; Vatti, R.; Luzi, P.; Tosi, P.; Pileri, S.; Cottier, H.
Flow cytometric analysis of early and advanced gastric-cancer
1987-01-01 Leoncini, L.; Vindigni, C.; Minacci, C.; Nuti, S.; Lavarini, E.; Cintorino, M.; Pinto, E.; Destefano, A.; Tosi, P.
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients
2009-01-01 Di Giacomo, A; Danielli, R; Calabrò, L; Guidoboni, M; Miracco, C; Biagioli, M; Mazzei, M; Altomonte, Maresa; Maio, M
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy
2009-01-01 Danielli, R.; Queirolo, P.; Testori, A.; Plummer, R.; Razis, E.; Sileni Chiarion, V.; Calabrò, L.; Di Giacomo, A. M.; Ridolfi, R.; Maio, M.
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients
2009-01-01 Di Giacomo, A. M.; Danielli, R.; Calabro, L.; Bertocci, E.; Nannicini, C.; Miracco, C.; Biagioli, M.; Mazzei, M. A.; Altomonte, M.; Maio, M.
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients
2009-01-01 Altomonte, M.; Queirolo, P.; Testori, A.; Ascierto, P.; Danielli, R.; Di Giacomo, A. M.; Sileni Chiarion, V.; Del Vecchio, M.; Ridolfi, R.; Maio, M.
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients
2009-01-01 Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M
Bcg vs. Gemcitabina per la terapia endovescicale del carcinoma uroteliale ad alto rischio: Studio prospettico randomizzato
2008-01-01 Del Zingaro, M; Costantini, E; Lazzeri, M; Mearini, L; Mearini, E; Giannantoni, A; Zucchi, A; Joannidou, K; Bini, V; Porena, M
Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
---|---|---|---|---|
Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma | 1-gen-2011 | Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J | - | |
Estratto della tesi di dottorato: “Il principio del vivente nelle anonime Questiones super librum de anima (ms. Siena, Bibl. Com. degli Intronati L.III.21, ff. 136ra-174ra”, | 1-gen-2005 | Bernardini, Paola | - | |
Guest Editorial “Secure lightweight crypto-hardware” | 1-gen-2017 | Acosta, A.; Addabbo, T. | - | |
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy | 1-gen-2019 | Bargagli, E; Bergantini, L; Cameli, P; D'Alessandro, M; Bini, L; Rottoli, P; Landi, C | - | |
Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European expanded access programme (EAP) | 1-gen-2012 | Maio, M; Chiarion Sileni, V; Pilla, L; Nicoletti, Svl; Di Guardo, L; Queirolo, P; De Galitiis, F; Mandala, M; Guida, M; Ascierto, Pa | - | |
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases | 1-gen-2012 | Maio, M; Testori, A; Ascierto, Pa; Ridolfi, R; Santinami, M; Pilla, L; Queirolo, P; Grosso, M; Simeone, E; Vittoria, S; Nicoletti, L; Rivoltini, L; Ferrucci, Pf; Parmiani, G; DI GIACOMO, ANNA MARIA | - | |
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma | 1-gen-2012 | Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M | - | |
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) | 1-gen-2011 | Johnston, K; Levy, Ar; Lorigan, P; Maio, M; Lebbé, C; Middleton, M; Testori, A; Bédane, C; Konto, C; Dueymes, A; van Baardewijk, M | - | |
Morphological and functional characterization of IL12 Receptor beta2 chain on intestinal epithelial cells: implications for local and systemic immunoregulation | 1-gen-2018 | Nicoletti, C.; Regoli, M.; Pacini, A.; Branca, J. J. V.; Man, A. L.; Morucii, G.; Narbad, A.; Gulisano, M.; Bertelli, E. | - | |
Guidelines Versus Measurements in Real Setting: Modelling Microbial Airborne Contamination and Air Flow in Operating Theaters | 1-gen-2018 | Vonci, Niccolò; Spataro, Giuseppe; De Marco, Maria Francesca; Nante, Nicola; Cevenini, Gabriele; Messina, Gabriele | - | |
Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma | 1-gen-2013 | Maio, M; Bondarenko, I; Robert, C; Thomas, L; Garbe, C; Testori, A; Lu, H; Chin, K; Wolchok, J | - | |
Five-year survival rates for patients (pts) with metastatic melanoma (mm) treated with ipilimumab (ipi) in phase II trials | 1-gen-2012 | Lebbe, C; Weber, Js; Maio, M; Neyns, B; Harmankaya, K; Chin, K; Mcdowell, Do; Cykowski, L; Mchenry, Mb; Wolchok, Jd | - | |
Expression of p34(cdc2) and cyclin B-1 in Hodgkin's disease and anaplastic large cell lymphomas | 1-gen-1997 | Leoncini, L.; Megha, T.; Lazzi, S.; Bellan, C.; Vatti, R.; Luzi, P.; Tosi, P.; Pileri, S.; Cottier, H. | - | |
Flow cytometric analysis of early and advanced gastric-cancer | 1-gen-1987 | Leoncini, L.; Vindigni, C.; Minacci, C.; Nuti, S.; Lavarini, E.; Cintorino, M.; Pinto, E.; Destefano, A.; Tosi, P. | - | |
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients | 1-gen-2009 | Di Giacomo, A; Danielli, R; Calabrò, L; Guidoboni, M; Miracco, C; Biagioli, M; Mazzei, M; Altomonte, Maresa; Maio, M | - | |
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy | 1-gen-2009 | Danielli, R.; Queirolo, P.; Testori, A.; Plummer, R.; Razis, E.; Sileni Chiarion, V.; Calabrò, L.; Di Giacomo, A. M.; Ridolfi, R.; Maio, M. | - | |
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients | 1-gen-2009 | Di Giacomo, A. M.; Danielli, R.; Calabro, L.; Bertocci, E.; Nannicini, C.; Miracco, C.; Biagioli, M.; Mazzei, M. A.; Altomonte, M.; Maio, M. | - | |
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients | 1-gen-2009 | Altomonte, M.; Queirolo, P.; Testori, A.; Ascierto, P.; Danielli, R.; Di Giacomo, A. M.; Sileni Chiarion, V.; Del Vecchio, M.; Ridolfi, R.; Maio, M. | - | |
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients | 1-gen-2009 | Altomonte, M; Queirolo, P; Testori, A; Ascierto, P; Danielli, R; DI GIACOMO, ANNA MARIA; Sileni Chiarion, V; Del Vecchio, M; Ridolfi, R; Maio, M | - | |
Bcg vs. Gemcitabina per la terapia endovescicale del carcinoma uroteliale ad alto rischio: Studio prospettico randomizzato | 1-gen-2008 | Del Zingaro, M; Costantini, E; Lazzeri, M; Mearini, L; Mearini, E; Giannantoni, A; Zucchi, A; Joannidou, K; Bini, V; Porena, M | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista1829
Data di pubblicazione
- 2020 - 2024144
- 2010 - 2019699
- 2000 - 2009722
- 1990 - 1999227
- 1980 - 198934
- 1974 - 19793
Editore
- Eular Publishers:Missionsstrasse 36, CH-4012 Basel Switzerland:011 41 61 2646470, EMAIL: eular@reinhardt.ch, Fax: 011 41 61 26464881
- F K Schattauer Verlagsgesellschaft mbH:Postfach 104545, D-70040 Stuttgart Germany:011 49 711 2298726, EMAIL: info@schattauer.de, INTERNET: http://www.schattauer.de, Fax: 011 49 711 22987501
- Firenze University Press1
- Fondaz Ferrata Storti:Strada Nuova 134, 27100 Pavia Italy:011 39 0382 531182, EMAIL: office@haematologica.it, Fax: 011 39 0382 277211
Rivista
- EUROPEAN JOURNAL OF PUBLIC HEALTH192
- MULTIPLE SCLEROSIS72
- URODINAMICA60
- EUROPEAN UROLOGY. SUPPLEMENTS39
- PEDIATRIC RESEARCH37
- ANNALS OF ONCOLOGY26
- THE JOURNAL OF UROLOGY26
- ACTA OPHTHALMOLOGICA24
- EUROPEAN RESPIRATORY JOURNAL23
- HELICOBACTER23
Keyword
- Hypoxia9
- Biomarkers8
- nonlinear analysis8
- biomarkers6
- cirrhosis6
- Idiopathic pulmonary fibrosis6
- thrombin6
- Caretta caretta5
- fractal analysis5
- botulinum a toxin4
Lingua
- eng1479
- ita129
- fre6
- und2
- ger1
- por1
Accesso al fulltext
- no fulltext1288
- reserved442
- open83
- internalNetwork13
- partially open3
Appartenenza
- Dipartimento di Biotecnologie Mediche369
- Dipartimento di Biotecnologie, Chimica e Farmacia107
- Dipartimento di Filologia e Critica delle Letterature Antiche e Moderne4
- Dipartimento di Giurisprudenza2
- Dipartimento di Ingegneria dell'Informazione e Scienze Matematiche19
- Dipartimento di Medicina Molecolare e dello Sviluppo534
- Dipartimento di Scienze della Formazione, Scienze Umane e della Comunicazione Interculturale1
- Dipartimento di Scienze della Vita253
- Dipartimento di Scienze Fisiche, della Terra e dell'Ambiente102
- Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze862